Clinical trial
An Open, Single-Arm, Multi-Center Clinical Study to Evaluate the Safety and Tolerability of Regulatory T Cells (Tregs) In the Treatment of Neurodegenerative Diseases
NCT06671236 is registered in ClinicalTrials.gov with Novabio Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open, Single-Arm, Multi-Center Clinical Study to Evaluate the Safety and Tolerability of Regulatory T Cells (Tregs) In the Treatment of Neurodegenerative Diseases
- Lead sponsor
- Novabio Therapeutics
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- November 21, 2024
- Completion date
- December 31, 2027
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
amyotrophic lateral sclerosis (als)